• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
XVIVO
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
    • Info
    • Ownership structure
    • Insiders (PDMRs)
  • Press releases
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Financial reports – ESEF
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
    • Capital Markets Day
    • Earnings calls
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • Code of Conduct
  • Environmental Policy
  • Code of Conduct for Suppliers
  • Privacy policy
  • Contact us
  • Subscribe
  • Thank you
  • Error

Press releases 2013

  • All press releases
  • Regulatory Press Releases
2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
2013-12-19 14:00
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
Unikt samarbete mellan OPO och transplantationsklinik inledd i XVIVOs amerikanska studie
2013-12-19 14:00
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
Unique collaboration between OPO and transplant center initiated in XVIVO’s US clinical trial
2013-11-07 08:30
News
IR
English
Regulatory
VPML
Report
Interim
Q3
Interim report January - September 2013
2013-11-07 08:30
News
IR
Swedish
Regulatory
VPML
Report
Interim
Q3
Delårsrapport januari–september 2013
2013-11-06 11:00
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO utökar NOVEL studien i USA
2013-11-06 11:00
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO expands the NOVEL study in the USA
2013-10-29 10:30
News
IR
English
Corporate Information
Other Corporate Information
Conference call interim report
2013-10-29 10:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Telekonferens avseende delårsrapport
2013-10-25 10:30
News
IR
English
Regulatory
VPML
Corporate Information
Staff change
Dr. Joel Cooper accepted to be new Medical Advisor to XVIVO perfusion
2013-10-25 10:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Presentation
Dr Joel Cooper ny Medical Advisor för XVIVO Perfusion
2013-10-18 10:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO lanserar XPS™ systemet i Europa
2013-10-18 10:30
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO launches the XPS™ system in Europe
2013-10-16 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Valberedning i XVIVO Perfusion AB (publ)
2013-10-16 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Election Committee of XVIVO Perfusion AB (publ)
2013-10-11 11:50
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO Perfusion files lawsuit against Vivoline
2013-10-11 11:50
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO Perfusion stämmer Vivoline
2013-09-20 16:55
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
NOVEL trial recruitment of patients complete, FDA has decided that an expert panel meeting will be held Q1 of 2014.
2013-09-20 16:55
News
IR
Swedish
Regulatory
VPML
Corporate Information
General meeting
Notice
STEEN Solution™ studien i USA färdigrekryterad, FDA har bestämt att ett expertmöte ska hållas i första kvartalet 2014.
2013-07-11 08:30
News
IR
Swedish
Regulatory
VPML
Report
Interim
Q2
Delårsrapport januari–juni 2013
2013-07-11 08:30
News
IR
English
Regulatory
VPML
Report
Interim
Q2
Interim report January - June 2013
2013-07-09 08:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
Samtliga patienter inkluderade i den amerikanska NOVEL studien med STEEN Solution™
2013-07-09 08:30
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
All patients included in the NOVEL trial in the USA with STEEN Solution™
2013-07-04 16:30
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
Share warrant program fully subscribed
2013-07-04 16:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
Teckningsoptionsprogrammet fulltecknat
2013-07-01 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Telekonferens avseende delårsrapport
2013-07-01 08:30
News
IR
English
Corporate Information
Other Corporate Information
Conference call interim report
2013-05-08 08:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
General meeting
Report of the AGM
Kommuniké från årsstämma i XVIVO Perfusion AB (publ)
2013-05-08 08:30
News
IR
English
Regulatory
VPML
Corporate Information
General meeting
Report of the AGM
Report from Annual General Meeting of XVIVO Perfusion AB (publ)
2013-04-19 13:00
News
IR
Swedish
Regulatory
VPML
Report
Interim
Q1
Delårsrapport januari–mars 2013
2013-04-19 13:00
News
IR
English
Regulatory
VPML
Report
Interim
Q1
Interim report January-March 2013
2013-04-15 14:00
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
Annual report 2012
2013-04-15 14:00
News
IR
Swedish
Regulatory
VPML
Report
Annual
Årsredovisning 2012
2013-04-12 11:45
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
Clarification of XVIVO Perfusion’s rights to Professor Stig Steen’s media for the preservation and evaluation of organs
2013-04-12 11:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
Klarläggande XVIVO Perfusions rättigheter till Professor Stig Steens medier för preservation och evaluering av organ
2013-04-11 11:30
News
IR
English
Corporate Information
Other Corporate Information
Conference call interim report
2013-04-11 11:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Telekonferens avseende delårsrapport
2013-04-08 15:00
News
IR
English
Regulatory
VPML
Corporate Information
General meeting
Notice
Annual General Meeting of XVIVO Perfusion AB (publ)
2013-04-08 15:00
News
IR
Swedish
Regulatory
VPML
Corporate Information
General meeting
Notice
Kallelse till årsstämma I XVIVO Perfusion AB (publ)
2013-02-19 16:30
News
IR
English
Regulatory
VPML
Report
Interim
Yearend
Report on operations 2012
2013-02-19 16:30
News
IR
Swedish
Regulatory
VPML
Report
Interim
Yearend
BOKSLUTSKOMMUNIKÉ 2012
2013-02-15 12:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Telekonferens avseende bokslutskommuniké 2012
2013-02-15 12:30
News
IR
English
Corporate Information
Other Corporate Information
Conference call on the Report on Operations 2012
2013-02-07 08:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
Ytterligare stämning mot Vitrolifes amerikanska dotterbolag rörande Perfadex
2013-02-07 08:30
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
Further lawsuits filed against Vitrolife’s American subsidiary regarding Perfadex
2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
2013-12-19 14:00
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
Unikt samarbete mellan OPO och transplantationsklinik inledd i XVIVOs amerikanska studie
2013-12-19 14:00
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
Unique collaboration between OPO and transplant center initiated in XVIVO’s US clinical trial
2013-11-07 08:30
News
IR
English
Regulatory
VPML
Report
Interim
Q3
Interim report January - September 2013
2013-11-07 08:30
News
IR
Swedish
Regulatory
VPML
Report
Interim
Q3
Delårsrapport januari–september 2013
2013-11-06 11:00
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO utökar NOVEL studien i USA
2013-11-06 11:00
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO expands the NOVEL study in the USA
2013-10-25 10:30
News
IR
English
Regulatory
VPML
Corporate Information
Staff change
Dr. Joel Cooper accepted to be new Medical Advisor to XVIVO perfusion
2013-10-25 10:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Presentation
Dr Joel Cooper ny Medical Advisor för XVIVO Perfusion
2013-10-18 10:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO lanserar XPS™ systemet i Europa
2013-10-18 10:30
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO launches the XPS™ system in Europe
2013-10-16 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Valberedning i XVIVO Perfusion AB (publ)
2013-10-16 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Election Committee of XVIVO Perfusion AB (publ)
2013-10-11 11:50
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO Perfusion files lawsuit against Vivoline
2013-10-11 11:50
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
XVIVO Perfusion stämmer Vivoline
2013-09-20 16:55
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
NOVEL trial recruitment of patients complete, FDA has decided that an expert panel meeting will be held Q1 of 2014.
2013-09-20 16:55
News
IR
Swedish
Regulatory
VPML
Corporate Information
General meeting
Notice
STEEN Solution™ studien i USA färdigrekryterad, FDA har bestämt att ett expertmöte ska hållas i första kvartalet 2014.
2013-07-11 08:30
News
IR
Swedish
Regulatory
VPML
Report
Interim
Q2
Delårsrapport januari–juni 2013
2013-07-11 08:30
News
IR
English
Regulatory
VPML
Report
Interim
Q2
Interim report January - June 2013
2013-07-09 08:30
News
IR
Swedish
Regulatory
VPML
Corporate Information
Other Corporate Information
Samtliga patienter inkluderade i den amerikanska NOVEL studien med STEEN Solution™
2013-07-09 08:30
News
IR
English
Regulatory
VPML
Corporate Information
Other Corporate Information
All patients included in the NOVEL trial in the USA with STEEN Solution™
Next
About us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on three continents. The company is listed on Nasdaq.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivogroup.com

 

Report a violations or breach here: Whistleblower

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2023 XVIVO. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO. Read more about Cookies

Approve